Doms № 1 -2022

Doms № 1 -2022 (84-51 p)

Positive effects of Vildagliptin and its combinations
with Metformin in therapy of patients with type 2 diabetes
and comorbid pathology
Sayenko Ya. A.

Abstract

In recent years, in the pathogenesis of such diseases as diabetes, obesity, hypertension, such an important link of pathogenesis as inflammation is also considered. Inflammation of any genesis is included in its own in the development of microcirculation disorders, which in turn are associated with endothelial dysfunction. Therefore, the latter is considered a common link in the pathogenesis of type 2 diabetes, obesity and their complications. Modern treatment of type 2 diabetes involves the use of Metformin and highly selective dipeptidyl peptidase 4 (DPP-4) inhibitors, in particular Vildagliptin. There are also combinations of these two medications, as, for example, in the composition of the medication “Aiglimet” produced by Ukrainian company Farmak. This review summarizes the results of the latest global research effects of combination of the medications Metformin and Vildagliptin on the course of type 2 diabetes, obesity, cardiovascular diseases, cognitive dysfunctions, etc. There are also data on molecular mechanisms of the endothelioprotective functions of these medications.

Keywords: type 2 diabetes, endothelial dysfunction, treatment of type 2 diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors.

References

  1. P. C. van der Vorst, L. J. F. Peters, M. Müller, S. Gencer, Y. Yan, C. Weber, Y. Döring, G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis, Front Pharmacol 10, 531 (2019).
  2. Abbasalizad Farhangi, M. Vajdi, L. Nikniaz, Z. Nikniaz, The interaction between dietary inflammatory index and 6 P21 rs2010963 gene variants in metabolic syndrome, Eat Weight Disord (2019), doi:10.1007/s40519-019-00729-1.

  3. G. Bentley, G. Pugh, L. R. Gledhill, R. J. Flynn, An analysis of the immune compartment within bovine adipose tissue, Dev. Comp. Immunol. 100, 103411 (2019).

  4. Е.А. Шестакова. Возможности ранней комбинированной терапии сахарного диабета 2-го типа. // Проблемы эндокринологии, 5, 2015. doi: 10.14341/probl201561556-59.

  5. Ida Pernicova & Márta Korbonits. Metformin—mode of action and clinical implications for diabetes and cancer. // Nature Reviews Endocrinology, 2014;Vol.10,pp143–156.

 

  1. Peng Gao, Li Li, Xiao Wei, et al. Activation of Transient Re- ceptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction // Hypertension. 2020;75:00-00. DOI: 10.1161/Hypertensionaha.119.13778.

  2. Alessandra Schiappacassa, Priscila A. Maranhão, Maria das Graças Coelho de Souza, et al. Acute E_ects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial. // J. Clin. Med. 2020, 9, 3228; doi:10.3390/jcm9103228.

  3. Dong-Yi Chen, Yan-Rong Li, Chun-Tai Mao, et al. Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. // J Diabetes Investig. 2020;11(1):110-124. doi: 10.1111/jdi.13078.

  4. Yosuke Ishida, Hiroki Murayama, Yohei Shinfukuб et al. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. // Expert Opinion on Drug Safety, 2020, DOI: 10.1080/14740338.2020.1740679

  5. John J.V. McMurray, Piotr Ponikowski, Geremia B. Bolli, et al. Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure;(NCT00894868) (J Am Coll Cardiol HF 2017)

  6. Демидова Т.Ю., Куленок С.Г., Гасанзаде П.А. Патогенетические предпосылки применения ингибиторов дипепти- дилпептидазы-4 в управлении сахарным диабетом типа 2. Consilium Medicum. 2017; 19 (4): 23–28.

  7. Roberto Trevisan. The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction. // Diabetes Ther. 2017, DOI 10.1007/s13300-017-0302-3.

  8. Rachael Williams, Wolfgang Kothny, Carmen Serban, Sandra Lopez‐Leon, Raymond Schlienger. Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study. // Endocrinol Diab Metab. 2019;2:e00052. DOI: 10.1002/edm2.52.

  9. Gillian M. Keating. Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. // Drugs (2014) 74:587–610, DOI 10.1007/s40265-014-0199-3

  10. Marion Munch, Laurent Meyer, Thierry Hannedouche, et al. Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study. // Diabetes Obes Metab. 2020;22:978–987. DOI: 10.1111/dom.13988

  11. Salah Shelbaya & Sameh Rakha (2017): Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study, Current Medical Research and Opinion, DOI: 10.1080/03007995.2016.1277199.
  12. Ibrahim El Ebrashy, Nabil El Kafrawy, Rana Raouf, Diana Yousry. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real- world setting in Egypt: The OMEGA study. // Diabetes research and clinical practice, 162, (2020), 108042. https:// doi.org/10.1016/j.diabres.2020.108042
  13. David R Matthews, Päivi M Paldánius, Pieter Proot, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. // Lancet. 2019;394(10208):1519-1529. doi: 10.1016/S0140- 6736(19)32131-2.
  14. Демидова Т.Ю., Кожевников А.А. Доверяй и VERIFY: роль комбинированной терапии метформином и ингибиторами дипептидилпептидазы-4 в дебюте сахар- ного диабета 2 типа. РМЖ. Медицинское обозрение. 2020;4(6):334–339. DOI: 10.32364/2587-6821-2020-4-6- 334-339.
  15. М.В. Шестакова, М.Б. Анциферов, А.С. Аметов, и др.. Какие новые возможности для клинической практики открывает исследование Verify и какова его ценность для пациентов с впервые выявленным сд 2 типа? Совместное заключение по итогам экспертного совета. 6 ноября 2019 г. // Сахарный диабет. 2020;23(1):106-110. doi: 10.14341/DM12404.
  16. Luc Van Gaal . Michel P. Hermans . Evis Daci. Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in ‘‘Real-World’’ Management of Type 2 Diabetes Mellitus: The G-FORCE Study. Diabetes Ther. 2019, https://doi.org/10.1007/s13300- 019-0601-y.
  17. Esra Ates Bulut, Zehra Yagmur Sahin Alak, Ozge Dokuzlar, et al. Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study. // Archives of Gerontology and Geriatrics 88 (2020) 104013. https://doi.org/10.1016/j. archger.2020.104013.